CL2024002627A1 - Formas polimorfas de aticaprant para su uso en el tratamiento del trastorno depresivo mayor. - Google Patents

Formas polimorfas de aticaprant para su uso en el tratamiento del trastorno depresivo mayor.

Info

Publication number
CL2024002627A1
CL2024002627A1 CL2024002627A CL2024002627A CL2024002627A1 CL 2024002627 A1 CL2024002627 A1 CL 2024002627A1 CL 2024002627 A CL2024002627 A CL 2024002627A CL 2024002627 A CL2024002627 A CL 2024002627A CL 2024002627 A1 CL2024002627 A1 CL 2024002627A1
Authority
CL
Chile
Prior art keywords
aticaprant
depressive disorder
major depressive
amorphous
crystalline forms
Prior art date
Application number
CL2024002627A
Other languages
English (en)
Spanish (es)
Inventor
Schmidt Mark
Popova Vanina
Savitz Adam
Melkote Rama
C Drevets Wayne
Gopal Srihari
Pemberton Darrel
Lagishetty Chakradhar
Fernandes Philippe
Kezic Iva
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of CL2024002627A1 publication Critical patent/CL2024002627A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CL2024002627A 2022-03-07 2024-09-02 Formas polimorfas de aticaprant para su uso en el tratamiento del trastorno depresivo mayor. CL2024002627A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263317475P 2022-03-07 2022-03-07

Publications (1)

Publication Number Publication Date
CL2024002627A1 true CL2024002627A1 (es) 2025-01-24

Family

ID=85706849

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002627A CL2024002627A1 (es) 2022-03-07 2024-09-02 Formas polimorfas de aticaprant para su uso en el tratamiento del trastorno depresivo mayor.

Country Status (14)

Country Link
US (3) US11998524B2 (https=)
EP (1) EP4489747A1 (https=)
JP (1) JP2025508051A (https=)
KR (1) KR20240156409A (https=)
CN (1) CN119156211A (https=)
AU (1) AU2023232536A1 (https=)
CA (1) CA3254365A1 (https=)
CL (1) CL2024002627A1 (https=)
CO (1) CO2024012158A2 (https=)
IL (1) IL315409A (https=)
JO (1) JOP20240197A1 (https=)
MX (1) MX2024010980A (https=)
TW (1) TW202345796A (https=)
WO (1) WO2023170550A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
WO2023170554A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457208A (en) 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
TR200103237T2 (tr) 1999-05-12 2002-04-22 F. Hoffmann-La Roche Ag İmidazodiazepin türevi
US20020052365A1 (en) 2000-10-05 2002-05-02 Mohler Hanns Selective anxiolytic therapeutic agents
JP2004518654A (ja) 2000-12-21 2004-06-24 ザ マクレーン ホスピタル コーポレーション 鬱病の治療法
US6974824B2 (en) 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
DE60319812T2 (de) 2002-03-28 2009-04-23 Wisys Technology Foundation, Inc., Madison Angstlösende wirkstoffe mit verminderten beruhigenden und ataktischen nebenwirkungen
KR101025633B1 (ko) 2002-09-19 2011-03-30 일라이 릴리 앤드 캄파니 오피오이드 수용체 안타고니스트로서의 디아릴 에테르
ATE406360T1 (de) 2003-03-07 2008-09-15 Lilly Co Eli Antagonisten der opioidrezeptoren
EP1613597B1 (en) 2003-03-07 2007-11-07 Eli Lilly and Company 6-substituted nicotinamide derivatives as opioid receptor antagonists
CA2549009A1 (en) 2003-12-12 2005-07-07 Eli Lilly And Company Opioid receptor antagonists
ES2390459T3 (es) 2003-12-22 2012-11-13 Eli Lilly And Company Antagonistas de receptores de opioides
DE602005022572D1 (de) 2004-03-12 2010-09-09 Lilly Co Eli Antagonisten des opioidrezeptors
EP1729759A4 (en) 2004-03-12 2008-04-02 Mclean Hospital Corp SALVINORINE DERIVATIVES AND ITS USES
ATE399164T1 (de) 2004-03-12 2008-07-15 Lilly Co Eli Antagonisten des opioidrezeptors
DE602005012380D1 (de) 2004-03-15 2009-03-05 Lilly Co Eli 4-(5-(aminomethyl)-indol-1-ylmethyl)benzamidderivate und verwandte verbindungen als opioidrezeptorantagonisten zur behandlung von fettleibigkeit
EP1735268B1 (en) 2004-03-15 2012-02-15 Eli Lilly And Company Opioid receptor antagonists
WO2007067714A2 (en) 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
JP5128578B2 (ja) 2006-04-04 2013-01-23 エモディス ゲーエムベーハー 解離性障害の治療のためのκ−オピオイド受容体アンタゴニスト含有組成物の利用
EP2049481A2 (en) 2006-08-09 2009-04-22 SmithKline Beecham Corporation Novel compounds as antagonists or inverse agonists for opioid receptors
EP2054383A2 (en) 2006-08-09 2009-05-06 SmithKline Beecham Corporation Novel compounds as antagonists or inverse agonists at opioid receptors
KR20090051778A (ko) 2006-09-08 2009-05-22 화이자 프로덕츠 인코포레이티드 다이아릴 에터 유도체 및 이의 용도
JP5345637B2 (ja) 2008-01-22 2013-11-20 イーライ リリー アンド カンパニー κ選択的オピオイド受容体アンタゴニスト
WO2012016569A1 (en) 2010-08-05 2012-02-09 Conrig Pharma Aps Deuterated tandospirone derivatives as 5-ht1a receptor agonists
ES2631607T3 (es) 2011-12-09 2017-09-01 Research Triangle Institute, International 4-Arilpiperazinas 1-sustituidas como antagonistas del receptor opioide kappa
ES2694352T3 (es) 2013-12-20 2018-12-20 H. Lundbeck A/S Uso de un antagonista del receptor opioide con actividad kappa, y vortioxetina para el tratamiento del trastorno depresivo con características melancólicas
WO2016156396A1 (en) 2015-03-30 2016-10-06 University Of Innsbruck Diphenethylamine derivatives which are inter alia useful as analgesics and methods for their production
US10709685B2 (en) 2015-05-28 2020-07-14 Georgetown University Use of methadone metabolites for treatment of anxiety and depression
EP3468540A4 (en) 2016-06-13 2020-03-18 Board Of Regents Of the University Of Texas System PHARMACEUTICAL COMPOSITIONS AND METHOD FOR TREATING PAIN
US20190240293A1 (en) 2016-07-26 2019-08-08 Flagship Pioneering Innovations V, Inc. Neuromodulating compositions and related therapeutic methods for the treatment of cancer by modulating an anti-cancer immune response
US11292783B2 (en) 2016-09-16 2022-04-05 Research Triangle Institute Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists
US10316021B2 (en) 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
AU2018234931B2 (en) 2017-03-17 2022-05-26 Blackthorn Therapeutics, Inc. Kappa opioid receptor antagonists and products and methods related thereto
PH12018000077B1 (en) 2017-07-05 2021-07-09 Frimline Private Ltd A pharmaceutical composition for neuropathic pain
US20190255036A1 (en) 2018-02-16 2019-08-22 Alexander Kariman Compound and method for reducing neuropathic pain and depression
JP7416751B2 (ja) 2018-03-23 2024-01-17 ユニバーシティ オブ カンザス 環状テトラペプチド類似体
US11491144B2 (en) 2018-03-30 2022-11-08 The Florida State University Research Foundation, Incorporated Methods of treating fragile X mental retardation syndrome
EP3870030A4 (en) 2018-10-23 2022-08-03 Blackthorn Therapeutics, Inc. SYSTEMS AND METHODS FOR SCREENING, DIAGNOSIS AND STRATIFICATION OF PATIENTS
US20200171025A1 (en) 2018-11-29 2020-06-04 Srinivasa Rao Parella Pharmaceutical composition comprising brexpiprazole and process for preparation thereof
US11266627B1 (en) * 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN114195693A (zh) * 2020-09-17 2022-03-18 广东东阳光药业有限公司 一种酰胺化合物的晶型及其制备方法
PH12023552963A1 (en) * 2021-05-04 2024-03-11 Janssen Pharmaceuticals Inc Compositions and methods for the treatment of depression
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
AU2023231493A1 (en) 2022-03-07 2024-10-24 Janssen Pharmaceuticals, Inc. Pure forms of crystalline aticaprant
WO2023170554A1 (en) 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant

Also Published As

Publication number Publication date
AU2023232536A1 (en) 2024-10-24
US20230277499A1 (en) 2023-09-07
US11998524B2 (en) 2024-06-04
IL315409A (en) 2024-11-01
CN119156211A (zh) 2024-12-17
JOP20240197A1 (ar) 2024-09-05
KR20240156409A (ko) 2024-10-29
US12171743B2 (en) 2024-12-24
WO2023170550A1 (en) 2023-09-14
CO2024012158A2 (es) 2024-09-30
JP2025508051A (ja) 2025-03-21
CA3254365A1 (en) 2023-09-14
EP4489747A1 (en) 2025-01-15
US20240316003A1 (en) 2024-09-26
US20250325515A1 (en) 2025-10-23
MX2024010980A (es) 2024-12-06
TW202345796A (zh) 2023-12-01

Similar Documents

Publication Publication Date Title
CL2024002627A1 (es) Formas polimorfas de aticaprant para su uso en el tratamiento del trastorno depresivo mayor.
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
NI202000080A (es) Inhibidores de magl
MX2021001558A (es) Inhibidores de itk de pirrolopirimidina.
CO2022000278A2 (es) Composiciones y métodos de tratamiento de una afección mediada por th2 usando prevotella
CL2019000304A1 (es) Fracciones de plasma en sangre como tratamiento para tratamientos cognitivos relacionados con el envejecimiento.
MX2018009917A (es) Vacuna contra el virus del zika.
CL2023000943A1 (es) Formas cristalinas de un compuesto farmacéutico.
MX2019012884A (es) Terapia de combinacion.
CO6390111A2 (es) Productos sanguíneos deshidratados por aspersión y métodos para elaborar los mismos
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CL2016000530A1 (es) Tratamiento de la osteoartritis y del dolor (divisional de sol. n°2298-13).
MX2020009602A (es) Formulaciones de pulverizacion de epinefrina.
CO2024007220A2 (es) Compuestos que contienen heteroátomos y usos de estos
MX2020004513A (es) Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican.
MX2017015292A (es) Composicion para tratar lesiones cerebrales.
EP3922264A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF SKIN DISEASES
AR131235A1 (es) Formas cristalinas de n,n-dimetiltriptamina y métodos para usarlas
MX2015015379A (es) Agonistas alfa adrenergicos para el tratamiento de traumatismo de tejidos.
CO2023013406A2 (es) Análogos de rifamicina en combinación con vancomicina y usos de los mismos
MX2024015839A (es) Composiciones y usos de psilocibina y psilocina
MX2020005310A (es) Producto de combinacion que comprende dicicloplatino y metodo de preparacion y uso del mismo.
MX2022000082A (es) Composiciones terapeuticas y metodos para tratar canceres.
AR128566A1 (es) Combinaciones de fármacos y métodos para tratar el cáncer de ovario
MX2020012728A (es) Medicinas de origen biologico y metodos para incrementar el cumplimiento del paciente.